Clinical Trial Update: Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome [Phase 3]

View source ↗

Summary

Phase 3 trial investigating erythropoietin for premature infants to assess effects on white matter injury and neurodevelopmental outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Palsy
• Intracranial Hemorrhage
• Periventricular Leukomalacia
• Premature Infants

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Premature Infants, Intracranial Hemorrhages | Phase 3 | Status: UNKNOWN